Market research
ISI.F Ionis Pharmaceuticals, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 8B
- P/E ratio
- Not available
- Analyst target
- 55.82
- Dividend yield
- Not available
- Beta
- 0.42
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US4622221004
- Market cap
- 8B
- P/E ratio
- Not available
- Analyst target
- 55.82
- Dividend yield
- Not available
- Beta
- 0.42
About
About Ionis Pharmaceuticals, Inc
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ISI.F discussion.
5 years, 5 months ago
Ionis Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 18.4% below its 200 day moving average.
From a valuation standpoint, the stock is 99.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.8.
Ionis Pharmaceuticals, Inc's total revenue sank by 41.3% to $290M since the same quarter in the previous year.
Its net income has dropped by 284.4% to $-340M since the same quarter in the previous year.
Finally, its free cash flow fell by 66.1% to $91M since the same quarter in the previous year.
Based on the above factors, Ionis Pharmaceuticals, Inc gets an overall score of 1/5.